Postmarketing surveillance of sumatriptan : patient population, efficacy, and adverse effects
A postmarketing surveillance survey of sumatriptan use comprised 32 questions including patient demographics, headache history, and sumatriptan experience. One hundred and forty-one questionnaires were sent out, and 109 patients responded; a total of 108 patients were included in the data analysis....
| Main Author: | |
|---|---|
| Format: | Others |
| Published: |
Scholarly Commons
1994
|
| Subjects: | |
| Online Access: | https://scholarlycommons.pacific.edu/uop_etds/2273 https://scholarlycommons.pacific.edu/cgi/viewcontent.cgi?article=3272&context=uop_etds |
| Summary: | A postmarketing surveillance survey of sumatriptan use comprised 32 questions including patient demographics, headache history, and sumatriptan experience. One hundred and forty-one questionnaires were sent out, and 109 patients responded; a total of 108 patients were included in the data analysis.
When compared with the national migraine population, on a percentage basis, significantly more African-Americans, females, young patients (less 45 years of age), and patients with higher mean incomes (>$45,000) were found in the present study of those taking sumatriptan (p
Males (N=8) and females (N=55) had a significantly different percentage of relief from the second dose of 94.7%±7.1 and 83.5%±24.4, respectively (p=0.01). An average percent of pain relief from the first dose in those weighing less or greater than 144 pounds was 76.5%±28.3 and 86.9%±16.4, respectively (p=0.023). The incidence of the adverse effects reported in this study was significantly greater than those reported in the literature (p<0.005). |
|---|